The DOI matches its Crossref record; 193 of the 193 references it cites were found in a registry or an index.
Dysregulation of growth factor signaling in human hepatocellular carcinoma
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Han, C. L., Michalopoulos, G. K., & Wu, T. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20560 · Cited by 129
RetractedMassagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Mammalian MAP kinase signalling cascades
Chang, L., & Karin, M. (2001) · Nature · doi:10.1038/35065000 · Cited by 5,111
Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions*
JONES, J. I., & CLEMMONS, D. R. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-3 · Cited by 4,710
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
MECHANISMS OF WNT SIGNALING IN DEVELOPMENT
Wodarz, A., & Nusse, R. (1998) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.14.1.59 · Cited by 2,017
Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling
Nakao, A., Afrakhte, M., Morn, A., Nakayama, T., Christian, J. L., Heuchel, R., Itoh, S., Kawabata, M., Heldin, N.-E., Heldin, C.-H., et al. (1997) · Nature · doi:10.1038/39369 · Cited by 1,809
Cellular Actions of the Insulin-Like Growth Factor Binding Proteins
Firth, S. M., & Baxter, R. C. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0033 · Cited by 1,750
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · cited 1×
“There are also multiple interactions of growth factor signaling pathways with p53, a central regulator of apoptosis, cell cycle and genomic stability (reviewed by Sherr and McCormick, 2002).”
Background
Cited by
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“%) present with abnormal AFP serum levels, a fact that has been recently correlated with a molecular subclass of aggressive HCCs (S2 class, EpCAM positive) [77–79].”
BackgroundInfluentialWNT signalling pathways as therapeutic targets in cancer
Anastas, J. N., & Moon, R. T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3419 · Cited by 1,911
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Molecular targeted therapies in hepatocellular carcinoma†
Llovet, J. M., & Bruix, J. (2008) · Hepatology · doi:10.1002/hep.22506 · Cited by 1,004
Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace
Baffy, G., Brunt, E. M., & Caldwell, S. H. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.027 · Cited by 858
Genomics and Signaling Pathways in Hepatocellular Carcinoma
Villanueva, A., Newell, P., Chiang, D., Friedman, S., & Llovet, J. (2007) · Seminars in Liver Disease · doi:10.1055/s-2006-960171 · Cited by 556
Hepatocellular carcinoma review: Current treatment, and evidence-based medicine
Raza, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i15.4115 · Cited by 464
Mechanisms of HBV-related hepatocarcinogenesis
Neuveut, C., Wei, Y., & Buendia, M. A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.10.033 · Cited by 421
Capece, D., Fischietti, M., Verzella, D., Gaggiano, A., Cicciarelli, G., Tessitore, A., Zazzeroni, F., & Alesse, E. (2013) · BioMed Research International · doi:10.1155/2013/187204 · Cited by 408
Inflammation and Liver Cancer: New Molecular Links
Berasain, C., Castillo, J., Perugorria, M. J., Latasa, M. U., Prieto, J., & Avila, M. A. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.03704.x · Cited by 390
The Curious Case of the HepG2 Cell Line: 40 Years of Expertise
Arzumanian, V. A., Kiseleva, O. I., & Poverennaya, E. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313135 · Cited by 387
The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis
Xu, D., Wang, Z., Xia, Y., Shao, F., Xia, W., Wei, Y., Li, X., Qian, X., Lee, J.-H., Du, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2183-2 · Cited by 360
The epidermal growth factor receptor: from development to tumorigenesis
Sibilia, M., Kroismayr, R., Lichtenberger, B. M., Natarajan, A., Hecking, M., & Holcmann, M. (2007) · Differentiation · doi:10.1111/j.1432-0436.2007.00238.x · Cited by 340
The EGF receptor is required for efficient liver regeneration
Natarajan, A., Wagner, B., & Sibilia, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704126104 · Cited by 320
Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment
Vilchez, V. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.823 · Cited by 312
Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements
Hoshida, Y., Toffanin, S., Lachenmayer, A., Villanueva, A., Minguez, B., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247131 · Cited by 310
MicroRNA-221 Targets Bmf in Hepatocellular Carcinoma and Correlates with Tumor Multifocality
Gramantieri, L., Fornari, F., Ferracin, M., Veronese, A., Sabbioni, S., Calin, G. A., Grazi, G. L., Croce, C. M., Bolondi, L., & Negrini, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0092 · Cited by 308
Epithelial–Mesenchymal Transition in Hepatocellular Carcinoma
van Zijl, F., Zulehner, G., Petz, M., Schneller, D., Kornauth, C., Hau, M., Machat, G., Grubinger, M., Huber, H., & Mikulits, W. (2009) · Future Oncology · doi:10.2217/fon.09.91 · Cited by 305
Shan, J., Shen, J., Liu, L., Xia, F., Xu, C., Duan, G., Xu, Y., Ma, Q., Yang, Z., Zhang, Q., et al. (2012) · Hepatology · doi:10.1002/hep.25745 · Cited by 296
“It has been demonstrated that high-level expression of IGF2 is an important autocrine protumorigenic event in HCC and that the activation of IGF2/IGF1R signaling is likely a progression switch by the function that promotes tumor cell dissemination and aggressive tumor behavior.(34,35) Therefore, the high level of IGF2…”
BackgroundDysregulation of apoptosis in hepatocellular carcinoma cells
Fabregat, I. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.513 · Cited by 280
Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma
Amann, T., Bataille, F., Spruss, T., Mühlbauer, M., Gäbele, E., Schölmerich, J., Kiefer, P., Bosserhoff, A., & Hellerbrand, C. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01087.x · Cited by 277
Nf2 /Merlin controls progenitor homeostasis and tumorigenesis in the liver
Benhamouche, S., Curto, M., Saotome, I., Gladden, A. B., Liu, C.-H., Giovannini, M., & McClatchey, A. I. (2010) · Genes & Development · doi:10.1101/gad.1938710 · Cited by 269
Fransvea, E., Angelotti, U., Antonaci, S., & Giannelli, G. (2008) · Hepatology · doi:10.1002/hep.22201 · Cited by 253
Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma
Bengochea, A., de Souza, M. M., Lefrançois, L., Le Roux, E., Galy, O., Chemin, I., Kim, M., Wands, J. R., Trepo, C., Hainaut, P., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604422 · Cited by 215
“…growth factors – that is, the insulinlike growth factor-II (IGF-II), hepatocyte growth factor (HGF), transforming growth factor-a (TGF-a), transforming growth factor-b (TGF-b), and wingless (Wnt) – in contributing to proliferation and antiapoptotic behaviour of HCC cells (Breuhahn et al, 2006).”
The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control
Guégan, J.-P., Frémin, C., & Baffet, G. (2012) · International Journal of Hepatology · doi:10.1155/2012/328372 · Cited by 56
Güller, M., Toualbi-Abed, K., Legrand, A., Michel, L., Mauviel, A., Bernuau, D., & Daniel, F. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.6339 · Cited by 52
Waly, A. A., El-Ekiaby, N., Assal, R. A., Abdelrahman, M. M., Hosny, K. A., El Tayebi, H. M., Esmat, G., Breuhahn, K., & Abdelaziz, A. I. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2018.01918 · Cited by 23
“In human hepatocarcinogenesis, overexpression of the secreted ligand IGF-II is of special importance for tumor formation and activation of the relevant receptor IGF1R correlates with poor patient prognosis (Breuhahn et al., 2006).”
BackgroundSelf-citationÁlvarez-Mercado, A. I., Caballeria-Casals, A., Rojano-Alfonso, C., Chávez-Reyes, J., Micó-Carnero, M., Sanchez-Gonzalez, A., Casillas-Ramírez, A., Gracia-Sancho, J., & Peralta, C. (2021) · Biomedicines · doi:10.3390/biomedicines9091158 · Cited by 12
Metadata
- Authors
- Breuhahn, K., Longerich, T., & Schirmacher, P.
- Venue
- Oncogene
- Published
- 2006-06-26
- Volume
- 25
- Issue
- 27
- Pages
- 3787-3800
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2050637252
- Cited by
- 391
- References
- 193
- FWCI
- 20.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.